- Home
- Articles
- latamerica
- hematologic cancer
Hematologic Cancer Articles & Analysis
8 articles found
CAR-T cell therapy has transformed the treatment landscape for hematological cancers, yet its widespread adoption remains limited by the complexity of ex vivo manufacturing. ...
Antibody-drug conjugates (ADCs), as emerging anticancer drugs, can deliver highly cytotoxic molecules directly to cancer cells to kill them. ADC is a monoclonal antibody covalently bound to cytotoxic chemical substances (payload) through linker. ...
In addition to its indirect effects, TSLP can directly act on CD4+ T cells, aiding in their proliferation, differentiation, and response to antigens[3]. TSLP and cancer New functions of TSLP have been discovered in the induction and progression of various tumors, including solid tumors such as breast, colon, and pancreatic cancers, as well as ...
In general, the incidence of ADA of ADCs is less in patients targeting hematologic cancer than in patients targeting solid cancer; Most ADA is specific to the monoclonal antibody domain of the ADC. ...
At present, chimeric antigen receptor T cell therapy (CAR-T) has made significant achievements in the treatment of specific hematological cancers, allowing patients with relapsed/refractory disease to survive longer and become healthier, but in clinical studies, cell therapy has actually not been successful in the treatment of patients with solid tumors, in part ...
Israeli-founded firm Sight Diagnostics, the company that uses AI and cutting-edge hardware to deliver rapid, complete blood count results, has signed a new research agreement with Jerusalem’s Shaare Zedek Medical Center to identify the possibility of blood cancer using a combination of images and data collected from Sight’s OLO device and patient clinical information ...
Malignant tumors Many malignant tumors can cause elevated serum amylase, the most common are ovarian cancer, lung cancer and multiple myeloma. Ectopic synthesis of tumor tissue is the cause of this phenomenon. ...
Visits to cancer clinics and hospitals risk exposing immunocompromised patients to infectious complications. ...